Moreover, the paper explores potential druggable targets for melanoma patients, including ERK5, CD73, ALDH1A1, PLA1A, and DMKN, which hold promise in addressing diagnostic hurdles and guiding personalized therapeutic decisions. The gene discussed is MAPK7; the disease is melanoma.